Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Cutaneous Lymphoma Clinical Trial

— LYMPHOTEQ  

Official title:

Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04520529
• Other study ID #: APHP190179
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 30, 2020
• Est. completion date: September 30, 2050

Study information

• Verified date: August 2020
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Adèle DE MASSON
• Phone: 01 42 49 43 19
• Email: adele.demasson[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: September 30, 2050
• Est. primary completion date: September 30, 2045
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age> 18 years old

• Informed consent signed by the patient

• Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria

Exclusion Criteria:

• Patient under guardianship or curatorship

• Lack of affiliation to social security

Related Conditions & MeSH terms

• Cutaneous Lymphoma
• Lymphoma

Intervention

Other:
• Biologic Samples
An additional punch from lesion skin as part of a skin biopsy performed as part of routine care. an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care. In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival		5 years
Secondary	Progression free survival		5 years
Secondary	Progression free survival		10 years
Secondary	Overall survival		10 years